Austar Lifesciences Limited, an investment holding company, provides integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. More Details
No risks detected for 6118 from our risk checks.
Flawless balance sheet with solid track record.
Share Price & News
How has Austar Lifesciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 6118 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 6118's weekly volatility (6%) has been stable over the past year.
7 Day Return
HK Life Sciences
1 Year Return
HK Life Sciences
Return vs Industry: 6118 exceeded the Hong Kong Life Sciences industry which returned 162.8% over the past year.
Return vs Market: 6118 exceeded the Hong Kong Market which returned 25.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Austar Lifesciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StIf You Like EPS Growth Then Check Out Austar Lifesciences (HKG:6118) Before It's Too Late
1 month ago | Simply Wall StAustar Lifesciences Limited's (HKG:6118) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
1 month ago | Simply Wall StIs Austar Lifesciences Limited's (HKG:6118) Shareholder Ownership Skewed Towards Insiders?
Is Austar Lifesciences undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 6118 (HK$12.42) is trading above our estimate of fair value (HK$0.89)
Significantly Below Fair Value: 6118 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 6118 is poor value based on its PE Ratio (158.6x) compared to the Asian Life Sciences industry average (47.1x).
PE vs Market: 6118 is poor value based on its PE Ratio (158.6x) compared to the Hong Kong market (11.7x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 6118's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 6118 is overvalued based on its PB Ratio (10.1x) compared to the HK Life Sciences industry average (9.1x).
How is Austar Lifesciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Austar Lifesciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Austar Lifesciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6118 has high quality earnings.
Growing Profit Margin: 6118's current net profit margins (2.6%) are higher than last year (0.8%).
Past Earnings Growth Analysis
Earnings Trend: 6118's earnings have grown significantly by 45.3% per year over the past 5 years.
Accelerating Growth: 6118's earnings growth over the past year (306.7%) exceeds its 5-year average (45.3% per year).
Earnings vs Industry: 6118 earnings growth over the past year (306.7%) exceeded the Life Sciences industry 59.6%.
Return on Equity
High ROE: 6118's Return on Equity (6%) is considered low.
How is Austar Lifesciences's financial position?
Financial Position Analysis
Short Term Liabilities: 6118's short term assets (CN¥1.1B) exceed its short term liabilities (CN¥805.7M).
Long Term Liabilities: 6118's short term assets (CN¥1.1B) exceed its long term liabilities (CN¥48.6M).
Debt to Equity History and Analysis
Debt Level: 6118's debt to equity ratio (6%) is considered satisfactory.
Reducing Debt: 6118's debt to equity ratio has reduced from 6.3% to 6% over the past 5 years.
Debt Coverage: 6118's debt is well covered by operating cash flow (166.3%).
Interest Coverage: 6118 earns more interest than it pays, so coverage of interest payments is not a concern.
What is Austar Lifesciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 6118's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 6118's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 6118's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 6118's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 6118 is not paying a notable dividend for the Hong Kong market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 6118's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mars Ho (58 yo)
Mr. Kwok Keung Ho, also known as Mars, is the Founder of Austar Lifesciences Limited and serves as its Chairman of the Board and Chief Executive Officer. Mr. Ho is responsible for overseeing the business, ...
CEO Compensation Analysis
Compensation vs Market: Mars 's total compensation ($USD143.47K) is below average for companies of similar size in the Hong Kong market ($USD422.59K).
Compensation vs Earnings: Mars 's compensation has been consistent with company performance over the past year.
Experienced Management: 6118's management team is seasoned and experienced (7 years average tenure).
Experienced Board: 6118's board of directors are considered experienced (7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Austar Lifesciences Limited's company bio, employee growth, exchange listings and data sources
- Name: Austar Lifesciences Limited
- Ticker: 6118
- Exchange: SEHK
- Founded: 1991
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$6.366b
- Shares outstanding: 512.58m
- Website: https://www.austar.com.hk
Number of Employees
- Austar Lifesciences Limited
- Chaowai Men Office Building
- Building B, Room 1801
Austar Lifesciences Limited, an investment holding company, provides integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. It opera...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/13 10:24|
|End of Day Share Price||2021/06/11 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.